Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
NCT02106546
Completed
The purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/13/2020
Locations: Northeast Arkansas Clinical Ch /ID# 128071, Jonesboro, Arkansas +224 locations
Conditions: Squamous Non-Small Cell Lung Cancer
Register for Updates
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
NCT01051570
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving carboplatin together with everolimus and prednisone may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving carboplatin togeth... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
11/06/2020
Locations: Northshore University Health System, Evanston, Illinois +3 locations
Conditions: Prostate Cancer
Register for Updates
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT01412229
Completed
This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2020
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina +2 locations
Conditions: Head and Neck Cancer
Register for Updates
Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer
NCT03699033
Withdrawn
Single center, single arm, Phase II study designed to evaluate the feasibility of hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with 4D PET/CT-based radiation treatment planning and concurrent carboplatin and paclitaxel in Stage IIIA or Stage IIIB NSCLC subjects.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2020
Locations: University of Toledo, Eleanor N. Dana Cancer Center, Toledo, Ohio
Conditions: Non Small Cell Lung Cancer
Register for Updates
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
NCT02392507
Completed
The purpose of the study is to determine if nab-paclitaxel and carboplatin chemotherapy plus necitumumab is effective and safe in participants with stage IV squamous non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2020
Locations: Florida Hospital Cancer Institute, Orlando, Florida
Conditions: Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Register for Updates
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
NCT03704467
Completed
The study was to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/21/2020
Locations: Marin Cancer Care, Inc., Greenbrae, California +12 locations
Conditions: Ovarian Cancer
Register for Updates
CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
NCT00576225
Withdrawn
This study is designed to test whether CT-2103/carboplatin provides improved overall survival compared to paclitaxel/carboplatin in women with NSCLC who have estradiol levels \>30 pg/ml.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/14/2020
Locations: Scottsdale Medical Specialists, Scottsdale, Arizona +43 locations
Conditions: NSCLC
Register for Updates
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
NCT03256136
Completed
This research study is studying a drug intervention as a possible treatment for lung cancer. The drugs involved in this study are: * Nivolumab * Carboplatin * Pemetrexed * Ipilimumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2020
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +2 locations
Conditions: Lung Cancer
Register for Updates
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
NCT01633970
Completed
This open-label, Phase Ib study that has six treatment arms is designed to assess the safety, pharmacology and preliminary efficacy of atezolizumab (MPDL3280A; an engineered anti-programmed death-ligand 1 \[PDL1\] antibody) administered with bevacizumab (Arm A) and with bevacizumab plus oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (FOLFOX) (Arm B), with carboplatin and paclitaxel (Arm C), with carboplatin and pemetrexed (Arm D), with carboplatin and nab-paclitaxel (Arm E), and with nab-pac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2020
Locations: University of Colorado Cancer Center, Aurora, Colorado +10 locations
Conditions: Cancer
Register for Updates
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer
NCT00723957
Completed
The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III (βIII)-tubulin-positive tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2020
Locations: Scripps Cancer Center, La Jolla, California +32 locations
Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer
Register for Updates
Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00551733
Terminated
RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, and paclitaxel poliglumex, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving carboplatin together with paclitaxel poliglumex is more effective than giving carboplatin together with paclitaxel in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel poliglume... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
10/02/2020
Locations: Scottsdale Medical Specialists, Scottsdale, Arizona +40 locations
Conditions: Lung Cancer
Register for Updates
Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00054210
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of chemotherapy is more effective in treating stage IIIB, stage IV, or recurrent non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of polyglutamate paclitaxel plus carboplatin to that of paclitaxel plus carboplatin in treating patients who have s... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/02/2020
Locations: Hematology and Oncology Associates of Alabama, Birmingham, Alabama +34 locations
Conditions: Lung Cancer
Register for Updates